scispace - formally typeset
Search or ask a question
Institution

German Red Cross

HealthcareBerlin, Germany
About: German Red Cross is a healthcare organization based out in Berlin, Germany. It is known for research contribution in the topics: Transplantation & Mesenchymal stem cell. The organization has 653 authors who have published 1146 publications receiving 40111 citations. The organization is also known as: Deutsches Rotes Kreuz & DRK.


Papers
More filters
Journal ArticleDOI
TL;DR: This substudy compares three different bacterial detection systems in order to investigate the prevalence of bacterially contaminated pool platelet concentrates and apheresis platelets.
Abstract: Background and Objectives Since 2004, bacterial screening of platelets has been required in the USA and is also done on a voluntary basis in many European countries. The German Red Cross blood donor services conducted a prospective multicentre study in order to investigate the prevalence of bacterially contaminated pool platelet concentrates and apheresis platelet concentrates. This substudy compares three different bacterial detection systems. Study Design and Methods Platelet concentrates were tested in parallel with BacT/ALERT, Scansystem‘ and Pall eBDS (n = 6307) in pool platelets. Apheresis platelets were tested in parallel with BacT/ALERT and Pall eBDS (n = 4730). All initially positive results were evaluated by a standardized procedure including evaluation by a microbiology reference laboratory. Results One in 6307 pool platelets were confirmed positive by BacT/ALERT, whereas Pall eBDS and Scansystem failed to detect these samples. Only three samples were initially reactive with Pall eBDS without proof of any bacteria strains. The rate of false-positive results was substantially higher for BacT/ALERT (0·25%, 28 in 11 037 tested samples) than for eBDS (0·03%, 3 in 11 037 tested samples) or Scansystem (0·0%, 0 in 6307 tested samples). Three of 4730 apheresis platelets were confirmed positive by BacT/ALERT. These were negative with Pall eBDS. Conclusion Sensitivity was best for BacT/ALERT, whereas specificity was enhanced for Pall eBDS and Scansystem. Scansystem required specially trained staff, whereas BacT/ALERT and Pall eBDS were easy, quick, user-friendly and objective methods.

44 citations

Journal ArticleDOI
TL;DR: A formal process validation was performed to support submission of the protocol for CE release, a prerequisite for clinical use of Prodigy CD34+ products, and the automatic system is suitable for routine clinical application.

44 citations

Journal ArticleDOI
TL;DR: It is demonstrated for the first time that YKL-39 is expressed on TAMs, predominantly positive for stabilin-1, but not by malignant cells or other stromal cells in human breast cancer.
Abstract: In breast cancer, the tumor microenvironment plays a critical role in the tumor progression and responses to therapy. Tumor-associated macrophages (TAMs) are major innate immune cells in tumor microenvironment that regulate intratumoral immunity and angiogenesis by secretion of cytokines, growth factors as well as chitinase-like proteins (CLPs), that combine properties of cytokines and growth factors. YKL-39 is a chitinase-like protein found in human and absent in rodents, and its expression in TAMs and role in breast cancer progression was not studied to date. Here for the first time we demonstrate that YKL-39 is expressed on TAMs, predominantly positive for stabilin-1, but not by malignant cells or other stromal cells in human breast cancer. TGF-beta in combination with IL-4, but not IL-4 alone was responsible of the stimulation of the production of YKL-39 in human primary macrophages. Mechanistically, stabilin-1 directly interacted with YKL-39 and acted as sorting receptor for targeting YKL-39 into the secretory pathway. Functionally, purified YKL-39 acted as a strong chemotactic factor for primary human monocytes, and induced angiogenesis in vitro. Elevated levels of YKL-39 expression in tumors after neoadjuvant chemotherapy (NAC) were predictive for increased risk of distant metastasis and for poor response to NAC in patients with nonspecific invasive breast carcinoma. Our findings suggest YKL-39 as a novel therapeutic target, and blocking of its activity can be combined with NAC in order to reduce the risk of metastasis in breast cancer patients.

44 citations

Journal ArticleDOI
TL;DR: The prevalence of bacterial contamination of random‐donor platelet concentrates is considerably lower than that of blood donations, and which key steps of the preparation procedure contribute to the elimination of bacteria was investigated.

44 citations


Authors

Showing all 658 results

NameH-indexPapersCitations
Johannes Oldenburg7258318790
Bodo Niggemann7127919475
Norbert Weissmann7138421187
Hubert Schrezenmeier6936016215
Triantafyllos Chavakis6524213247
Klaus Schwarz5820913407
Willy A. Flegel502336742
Rainer M. Bohle492356923
Torsten Tonn4815111328
Daniel Ricklin4614410713
Erhard Seifried442547967
Pamela S. Becker422576256
Karen Bieback4113510010
Halvard Bonig412164828
Julia Kzhyshkowska401265963
Network Information
Related Institutions (5)
Leiden University Medical Center
38K papers, 1.6M citations

83% related

Charité
64.5K papers, 2.4M citations

82% related

Karolinska University Hospital
33.5K papers, 1.2M citations

82% related

Fred Hutchinson Cancer Research Center
30.9K papers, 2.2M citations

81% related

St. Jude Children's Research Hospital
19.2K papers, 1.2M citations

81% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20233
20227
202198
2020126
201995
201891